a References 201 19. Gill PS, Meyer PR, Pavlova Z, Levine AM (1986) B cell acute lymphocytic leukemia in adults. Clinical, morphologic, and immunologic findings. J Clin Oncol 4(5):737 20. Baccarani M, Corbelli G, Amadori S, et al. (1982) Adolescent and adult acute lymphoblastic leukemia: Prognostic features and outcome of therapy. A study of 293 patients. Blood 60(3):677 21. Lazzarino M, Morra E, Alessandrino EP, et al. (1982) Adult acute lymphoblastic leukemia. Response to therapy according to presenting features in 62 patients. Eur J Cancer Clin Oncol 18(9):813 22. van der Reijden HJ, van Wering ER, van de Rijn JM, et al. (1983) Immunological typing of acute lymphoblastic leukaemia. Scand J Haematol 30(4):356 23. Lerede T, Bassan R, Rossi A, et al. (1996) Therapeutic impact of adult-type acute lymphoblastic leukemia regimens in B-cell/L3 acute leukemia and advanced-stage Burkitt’s lymphoma. Haematologica 81(5):442 24. Clarkson B, Ellis S, Little C, et al. (1985) <strong>Acute</strong> lymphoblastic leukemia in adults. Semin Oncol 12(2):160 25. Walters R, Kantarjian H, Keating M, et al. (1986) Effective, low-morbidity, outpatient induction therapy for adult acute lymphocytic leukemia (ALL). Proc Am Soc Clin Oncol 4:737 26. Barnett MJ, Greaves MF, Amess JA, et al. (1986) Treatment of acute lymphoblastic leukaemia in adults. Br J Haematol 64(3): 455 27. Patte C, Philip T, Rodary C, et al. (1986) Improved survival rate in children with stage III and IV B cell non-Hodgkin’s lymphoma and leukemia using multi-agent chemotherapy: Results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol 4(8):1219 28. Patte C, Michon J, Frappaz D, et al. (1994) Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: Experience with the LMB protocols of the SFOP (French Paediatric Oncology Society) in children and adults. Baillieres Clin Haematol 7(2):339 29. Murphy SB, Bowman WP, Abromowitch M, et al. (1986) Results of treatment of advanced-stage Burkitt’s lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 4(12):1732 30. Rosanda C, Cantu-Rajnoldi A, Invernizzi R, et al. (1992) B-cell acute lymphoblastic leukemia (B-ALL): A report of 17 pediatric cases. Haematologica 77(2):151 31. Patte C, Sakiroglu C, Ansoborlo S, Baruchel A, Plouvier E, Pacquement H, Babin-Boilletot A; Societe Francaise d‘Oncologie Pediatrique (2002) Urate-oxidase in the prevention and treatment of metabolic complications inpatients with B-cell lymphoma and leukemia, treated in the Societe Francaise d‘Oncologie Pediatrique LMB89 protocol. Ann Oncol 13:789–795 32. Reiter A, Schrappe M, Tiemann M, et al. (1999) Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 94(10):3294 33. Patte C, Auperin A, Michon J, et al. (2001) The société française d‘oncologie pédiatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97:3370–3379 34. Mead GM, Sydes MR, Walewski J, Grigg A, Hatton CS, Pescosta N, Guarnaccia C, Lewis MS, McKendrick J, Stenning SP, et al.; UKLG LY06 collaborators (2002) An international evaluation of CO- DOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: Results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13:1264–1274 35. Soussain C, Patte C, Ostronoff M, et al. (1995) Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 85(3):664 36. Troussard X, Leblond V, Kuentz M, et al. (1990) Allogeneic bone marrow transplantation in adults with Burkitt’s lymphoma or acute lymphoblastic leukemia in first complete remission. J Clin Oncol 8(5):809 37. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T, Santini G, Blaise D, Greinix H, Ferrant A,et al.; European Bone Marrow Transplantation (EBMT) Lymphoma Registry (2003) An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Trans 31:667–678 38. Pees HW, Radtke H, Schwamborn J, Graf N (1992) The BFM-protocol for HIV-negative Burkitt’s lymphomas and L3 ALL in adult patients: A high chance for cure. Ann Hematol 65(5):201 39. Todeschini G, Tecchio C, Degani D, et al. (1997) Eighty-one percent event-free survival in advanced Burkitt’s lymphoma/leukemia: No differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Ann Oncol 8(Suppl 1):77 40. Magrath I, Adde M, Shad A, et al. (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14(3):925 41. Kantarjian HM, O‘Brien S, Smith TL, et al. (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18(3):547 42. Hoelzer D, Baur K-H, Giagounidis A, et al. (2003) Short intensive chemotherapy with Rituximab seems successful in Burkitt NHL, mature B-ALL and other high-grade B-NHL. Blood 102:70a, (abstr 236) 43. Cabanillas ME, Thomas DA, Cortes J, et al. (2002) Outcome with hyper-CVAD and Rituximab in Burkitt (BL) and Burkitt-like (BLL) leukemia/lymphoma. Proc Am Soc Clin Oncol 22:574, (abstr 2309) 44. Preudhomme C, Dervite I, Wattel E, et al. (1995) Clinical significance of p53 mutations in newly diagnosed Burkitt’s lymphoma and acute lymphoblastic leukemia: A report of 48 cases. J Clin Oncol 13(4):812 45. Harbott J, Harder S, Haas OA, et al. (2003) Secondary chromosomal aberrations in childhood Burkitt’s leukemia/lymphoma-analysis of 182 complete caryotypes of patients treated according to the German-Austrian-Swiss BFM-NHL trials. Blood 102:11, 887a 46. Poirel HA, Heerema N, Swansbury J, et al. (2003) Prognostic value of recurrent chromosomal alterations in pediatric B-cell non- Hodgkin’s lymphoma: Report of 238 cases from the International FAB/LMB96 study. Blood 102:11, 391a 47. Philip T, Hartmann O, Pinkerton R, et al. (1993) Curability of relapsed childhood B-cell non-Hodgkin’s lymphoma after intensive first line therapy: A report from the Societe Francaise d‘Oncologie Pediatrique. Blood 81(8):2003
202 Chapter 15 · Burkitt’s <strong>Acute</strong> Lymphoblastic Leukemia (L 3ALL) in Adults 48. Spina M, Tirelli U, Zagonel V, et al. (1998) Burkitt’s lymphoma in adults with and without human immunodeficiency virus infection: A single-institution clinicopathologic study of 75 patients. Cancer 82(4):766 49. Levine AM (1992) Acquired immunodeficiency syndrome-related lymphoma [see comments]. Blood 80(1):8 50. Knowles DM, Chamulak GA, Subar M, et al. (1988) Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University <strong>Medical</strong> Center experience with 105 patients (1981–1986). Ann Intern Med 108(5):744 51. Odajnyk C, Subar M, Dugan M, et al. (1986) Clinical features and correlates with immunopathology and molecularbiology of a large group of patients with AIDS associated small non-cleaved lymphoma (SNCL). Blood 68:131a 52. Davi F, Delecluse HJ, Guiet P, et al. (1998) Burkitt-like lymphomas in AIDS patients: Characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin’s lymphomas. Burkitt’s Lymphoma Study Group. J Clin Oncol 16(12): 3788 53. Cortes J, Thomas D, Rios A, Koller C, O‘Brien S, Jeha S, Faderl S, Kantarjian H (2002) Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 94:1492–1499 54. Wang ES, Straus DJ, Teruya-Feldstein J, Qin J, Portlock C, Moskowitz C, Goy A, Hedrick E, Zelenetz AD, Noy A (2003) Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.Cancer 98:1196–1205
- Page 1 and 2:
E.H. Estey · S.H. Faderl · H. M.
- Page 3 and 4:
E. H. Estey Department of Leukemia
- Page 5 and 6:
VI Table of Contents 14 Philadelphi
- Page 7 and 8:
VIII Contributors S. H. Faderl Depa
- Page 9 and 10:
X Contributors D. Wartenberg Depart
- Page 11 and 12:
Therapy of AML Elihu Estey Contents
- Page 13 and 14:
a 1.2 · Standard Therapy 3 Table 1
- Page 15 and 16:
a 1.2 · Standard Therapy 5 Table 1
- Page 17 and 18:
a 1.2 · Standard Therapy 7 tween G
- Page 19 and 20:
a 1.2 · Standard Therapy 9 Fig. 1.
- Page 21 and 22:
a 1.2 · Standard Therapy 11 of tre
- Page 23 and 24:
a 1.2 · Standard Therapy 13 Table
- Page 25 and 26:
a 1.2 · Standard Therapy 15 permit
- Page 27 and 28:
a References 17 19. Care RS, Valk P
- Page 29 and 30:
a References 19 6-thioguanine in th
- Page 31 and 32:
Acute Myeloid Leukemia: Epidemiolog
- Page 33 and 34:
a 3.1 · Epidemiology 49 3.1.4 Gend
- Page 35 and 36:
a 3.2 · Etiology 51 part of the in
- Page 37 and 38:
a 3.2 · Etiology 53 for the develo
- Page 39 and 40:
a References 55 38. Crane MM, Stom
- Page 41 and 42:
Relapsed and Refractory Acute Myelo
- Page 43 and 44:
a 4.2 · Prognostic Factors in Pati
- Page 45 and 46:
a 4.3 · Treatment of Relapsed and
- Page 47 and 48:
a 4.4 · Hematopoietic Stem Cell Tr
- Page 49 and 50:
a 4.6 · Gemtuzumab Ozogamicin 65 T
- Page 51 and 52:
a 4.7 · Relapsed and Refractory Ac
- Page 53 and 54:
a 4.7 · Relapsed and Refractory Ac
- Page 55 and 56:
a References 71 The ability of immu
- Page 57 and 58:
a References 73 39. Vogler WR, McCa
- Page 59 and 60:
a References 75 95. Sievers EL, Lar
- Page 61 and 62:
Part II - Acute Lymphoblastic Leuke
- Page 63 and 64:
78 Chapter 5 · Acute Lymphoblastic
- Page 65 and 66:
80 Chapter 5 · Acute Lymphoblastic
- Page 67 and 68:
82 Chapter 5 · Acute Lymphoblastic
- Page 69 and 70:
84 Chapter 5 · Acute Lymphoblastic
- Page 71 and 72:
86 Chapter 5 · Acute Lymphoblastic
- Page 73 and 74:
88 Chapter 5 · Acute Lymphoblastic
- Page 75 and 76:
90 Chapter 5 · Acute Lymphoblastic
- Page 77 and 78:
92 Chapter 5 · Acute Lymphoblastic
- Page 79 and 80:
Molecular Biology and Genetics Meir
- Page 81 and 82:
a 6.3 · Structural Aberrations 97
- Page 83 and 84:
a 6.3 · Structural Aberrations 99
- Page 85 and 86:
a 6.5 · Molecular Aberrations 101
- Page 87 and 88:
a References 103 clear that homozyg
- Page 89 and 90:
a References 105 53. Chim CS, Tam C
- Page 91 and 92:
a References 107 122. Lennard L, Li
- Page 93 and 94:
Diagnosis of Acute Lymphoblastic Le
- Page 95 and 96:
a 8.3 · Cytochemistry and Immunoph
- Page 97 and 98:
a 8.5 · Cytogenetic and Molecular
- Page 99 and 100:
a 8.5 · Cytogenetic and Molecular
- Page 101 and 102:
a References 127 including the reti
- Page 103 and 104:
a References 129 47. Kita K, Shirak
- Page 105 and 106:
Acute Lymphoblastic Leukemia: Clini
- Page 107 and 108:
a 7.3 · Diagnosis 111 or neoplasti
- Page 109 and 110:
a 7.3 · Diagnosis 113 Fig. 7.2. Hi
- Page 111 and 112:
a 7.3 · Diagnosis 115 The vast maj
- Page 113 and 114:
a References 117 dren: Biologic bas
- Page 115 and 116:
General Approach to the Therapy of
- Page 117 and 118:
a 9.3 · New Agents 133 dose methot
- Page 119 and 120:
a References 135 4. Gökbuget N, Ho
- Page 121 and 122:
138 Chapter 10 · Recent Clinical T
- Page 123 and 124:
140 Chapter 10 · Recent Clinical T
- Page 125 and 126:
142 Chapter 10 · Recent Clinical T
- Page 127 and 128:
144 Chapter 10 · Recent Clinical T
- Page 129 and 130:
146 Chapter 11 · Conventional Ther
- Page 131 and 132: 148 Chapter 11 · Conventional Ther
- Page 133 and 134: 150 Chapter 11 · Conventional Ther
- Page 135 and 136: 152 Chapter 11 · Conventional Ther
- Page 137 and 138: 154 Chapter 11 · Conventional Ther
- Page 139 and 140: 156 Chapter 11 · Conventional Ther
- Page 141 and 142: 158 Chapter 11 · Conventional Ther
- Page 143 and 144: ALL Therapy: Review of the MD Ander
- Page 145 and 146: a 12.2 · The Hyper-CVAD Regimen in
- Page 147 and 148: a 12.3 · Subset-Specific Approache
- Page 149 and 150: Treatment of Adult ALL According to
- Page 151 and 152: a 13.2 · Therapy for Younger (15-6
- Page 153 and 154: a 13.3 · Therapy of Ph/BCR-ABL-Pos
- Page 155 and 156: a 13.5 · Prognostic Factors 173 13
- Page 157 and 158: a References 175 Only patients with
- Page 159 and 160: Philadelphia Chromosome-Positive Ac
- Page 161 and 162: a 14.2 · Molecular Biology of the
- Page 163 and 164: a 14.3 · Treatment of Ph+ ALL 181
- Page 165 and 166: a 14.4 · Hematopoietic Stem Cell T
- Page 167 and 168: a References 185 2. Kurzrock R, Sht
- Page 169 and 170: a References 187 56. Mori T, Manabe
- Page 171 and 172: a References 189 acute lymphoblasti
- Page 173 and 174: 192 Chapter 15 · Burkitt’s Acute
- Page 175 and 176: 194 Chapter 15 · Burkitt’s Acute
- Page 177 and 178: 196 Chapter 15 · Burkitt’s Acute
- Page 179 and 180: 198 Chapter 15 · Burkitt’s Acute
- Page 181: 200 Chapter 15 · Burkitt’s Acute
- Page 185 and 186: 204 Chapter 16 · Treatment of Lymp
- Page 187 and 188: 206 Chapter 16 · Treatment of Lymp
- Page 189 and 190: 208 Chapter 16 · Treatment of Lymp
- Page 191 and 192: 210 Chapter 16 · Treatment of Lymp
- Page 193 and 194: 212 Chapter 16 · Treatment of Lymp
- Page 195 and 196: 214 Chapter 16 · Treatment of Lymp
- Page 197 and 198: 216 Chapter 17 · The Role of Allog
- Page 199 and 200: 218 Chapter 17 · The Role of Allog
- Page 201 and 202: 220 Chapter 17 · The Role of Allog
- Page 203 and 204: 222 Chapter 17 · The Role of Allog
- Page 205 and 206: 224 Chapter 17 · The Role of Allog
- Page 207 and 208: 226 Chapter 17 · The Role of Allog
- Page 209 and 210: 228 Chapter 17 · The Role of Allog
- Page 211 and 212: 230 Chapter 18 · The Role of Autol
- Page 213 and 214: 232 Chapter 18 · The Role of Autol
- Page 215 and 216: 234 Chapter 18 · The Role of Autol
- Page 217 and 218: 236 Chapter 18 · The Role of Autol
- Page 219 and 220: 238 Chapter 19 · Novel Therapies i
- Page 221 and 222: 240 Chapter 19 · Novel Therapies i
- Page 223 and 224: 242 Chapter 19 · Novel Therapies i
- Page 225 and 226: 244 Chapter 19 · Novel Therapies i
- Page 227 and 228: 246 Chapter 19 · Novel Therapies i
- Page 229 and 230: 248 Chapter 20 · Minimal Residual
- Page 231 and 232: 250 Chapter 20 · Minimal Residual
- Page 233 and 234:
252 Chapter 20 · Minimal Residual
- Page 235 and 236:
254 Chapter 20 · Minimal Residual
- Page 237 and 238:
256 Chapter 20 · Minimal Residual
- Page 239 and 240:
258 Chapter 20 · Minimal Residual
- Page 241 and 242:
260 Chapter 20 · Minimal Residual
- Page 243 and 244:
262 Chapter 20 · Minimal Residual
- Page 245 and 246:
264 Chapter 21 · Central Nervous S
- Page 247 and 248:
266 Chapter 21 · Central Nervous S
- Page 249 and 250:
268 Chapter 21 · Central Nervous S
- Page 251 and 252:
270 Chapter 21 · Central Nervous S
- Page 253 and 254:
272 Chapter 21 · Central Nervous S
- Page 255 and 256:
274 Chapter 21 · Central Nervous S
- Page 257 and 258:
276 Chapter 22 · Relapsed Acute Ly
- Page 259 and 260:
278 Chapter 22 · Relapsed Acute Ly
- Page 261 and 262:
Emergencies in Acute Lymphoblastic
- Page 263 and 264:
a 23.5 · Hyperleukocytosis 283 LA
- Page 265 and 266:
a 23.9 · Neurological Complication
- Page 267 and 268:
a References 287 29. Hingorani AD,
- Page 269 and 270:
Subject Index A aberrant methylatio
- Page 271 and 272:
a Subject Index 291 CREB, see enhan
- Page 273 and 274:
a Subject Index 293 MUD, see matche